CMS has advised Scope Fluidics on an agreement with Bio-Rad Laboratories under which it received USD 30 million in settlement of conditional payments related to the sale of the Curiosity Diagnostics SPV.
Scope Fluidics is a Polish biotechnology company specializing in the design and development of projects based on microfluidic technologies in medical diagnostics and healthcare.
Bio-Rad Laboratories is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
According to CMS, “in 2022, Scope Fluidics sold Curiosity Diagnostics, which develops innovative technology solutions for the medical diagnostic and healthcare markets, to Bio-Rad Laboratories, a leading US med-tech company, along with its innovative PCR|One system. Scope Fluidics received USD 100 million as part of the first phase of the transaction, a record amount in the history of the Polish life science market. This new agreement increases the value of the transaction by an additional USD 30 million, which Scope Fluidics received in one payment and unconditionally, in lieu of conditional payments originally scheduled to be paid over the next three years.”
The CMS team included Partner Rafal Morek and Counsel Jan Markiewicz.
CMS did not respond to our inquiry on the matter.
